Shopping Cart

No products in the cart.

Weight_loss

Weight cycling and its effects on muscle mass, sarcopenia and sarcopenic obesity.

The prevalence of obesity is rising around the world, as the number of subjects dieting and experiencing weight loss followed by unintentional weight regain, the so-called weight cycling (WC). In this narrative review we sought to reveal the effects of...
๐Ÿ—“๏ธ 2025-04-15
๐Ÿ“ฐ Publication: Reviews In Endocrine & Metabolic Disorders
Read MoreWeight cycling and its effects on muscle mass, sarcopenia and sarcopenic obesity.

Weight Loss in Cancer and the 2017 Common Terminology Criteria for Adverse Events-Dangerous and Misleading.

Accurate toxicity reporting in cancer clinical trials is necessary to promote regulatory decision making. Up to 85% of those with some cancers (e.g., oesophagus, head and neck, and pancreas) experience significant progressive weight loss (WL) throughout treatment. Therefore, it is...
๐Ÿ—“๏ธ 2025-04-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreWeight Loss in Cancer and the 2017 Common Terminology Criteria for Adverse Events-Dangerous and Misleading.

Multicomponent Interventions for Adults With Cancer Cachexia: A Systematic Review.

Cancer cachexia has substantial impacts on people's quality of life. There is no current gold standard treatment, but the complex pathophysiology of cachexia suggests that a multitargeted and individualised treatment approach is needed. We aimed to evaluate the extent to...
๐Ÿ—“๏ธ 2025-04-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreMulticomponent Interventions for Adults With Cancer Cachexia: A Systematic Review.

Anamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.

Cancer cachexia presents a significant challenge, but the ghrelin agonist anamorelin shows promise as a potential treatment. This study examined whether the baseline systemic inflammatory response (SIR) (measured by the modified Glasgow Prognostic Score [mGPS]), low BMI or greater weight...
๐Ÿ—“๏ธ 2025-02-01
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAnamorelin Efficacy in Non-Small-Cell Lung Cancer Patients With Cachexia: Insights From ROMANA 1 and ROMANA 2.

Corrigendum to "Identifying cancer cachexia in patients without weight loss information: machine learning approaches to address a real-world challenge" Am J Clin Nutr 116 (2022) 1229-1239.

๐Ÿ—“๏ธ 2025-02-12
๐Ÿ“ฐ Publication: American Journal Of Clinical Nutrition
Read MoreCorrigendum to "Identifying cancer cachexia in patients without weight loss information: machine learning approaches to address a real-world challenge" Am J Clin Nutr 116 (2022) 1229-1239.

Brown adipose tissue is associated with reduced weight loss and risk of cancer cachexia: A retrospective cohort study.

Brown adipose tissue (BAT) has been mainly investigated as a potential target against cardiometabolic disease, but it has also been linked to cancer-related outcomes. Although preclinical data support that BAT and the thermogenic adipocytes in white adipose tissue may play...
๐Ÿ—“๏ธ 2024-12-30
๐Ÿ“ฐ Publication: Clinical Nutrition
Read MoreBrown adipose tissue is associated with reduced weight loss and risk of cancer cachexia: A retrospective cohort study.

Growth Differentiation Factor-15 Isย Associated With Congestion-Related Anorexia and Weight Loss in Advancedย Heartย Failure.

Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy. This study aims to investigate the relationships between GDF-15 levels, anorexia, cachexia, and clinical outcomes in patients with advanced...
๐Ÿ—“๏ธ 2025-01-08
๐Ÿ“ฐ Publication: Jacc-Heart Failure
Read MoreGrowth Differentiation Factor-15 Isย Associated With Congestion-Related Anorexia and Weight Loss in Advancedย Heartย Failure.

Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of โ‰ฅ50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

This retrospective, multicenter cohort study aimed to determine whether cancer cachexia serves as a biomarker for determining the most effective treatment for patients having non-small-cell lung cancer (NSCLC) with high programmed death ligand 1 (PD-L1) expression treated with immune checkpoint...
๐Ÿ—“๏ธ 2024-12-16
Read MoreClinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of โ‰ฅ50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

A fluorescent aptasensor for deoxynivalenol detection based on Nb.BbvCI-assisted targeted-responsive three-way junctions integrated DNA walking machine.

Deoxynivalenol (DON) contamination in cereals is a widespread issue with global implications, necessitating the development of efficient detection methods. Here, a fluorescent aptasensor integrating target-responsive DNA three-way junction (TWJ) and DNA walking machine was developed to detect DON. The DON-specific...
๐Ÿ—“๏ธ 2024-12-06
๐Ÿ“ฐ Publication: Food Chemistry
Read MoreA fluorescent aptasensor for deoxynivalenol detection based on Nb.BbvCI-assisted targeted-responsive three-way junctions integrated DNA walking machine.

Prognostic Impact and Prevalence of Cachexia in Patients With Heart Failure: A Systematic Review and Meta-Analysis.

Cachexia, defined as the combination of weight loss, weakness, fatigue, anorexia and abnormal biochemical markers based on Evans' criteria, is known to exacerbate the prognosis of heart failure (HF) patients. This systematic review and meta-analysis investigates the prognostic impact and...
๐Ÿ—“๏ธ 2024-10-30
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MorePrognostic Impact and Prevalence of Cachexia in Patients With Heart Failure: A Systematic Review and Meta-Analysis.

Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?

Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and combination therapies is approaching magnitudes achieved with surgery. However, as more weight loss is achieved, there is concern for potential adverse effects on muscle...
๐Ÿ—“๏ธ 2024-10-14
๐Ÿ“ฐ Publication: Circulation
Read MoreMuscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?

Sarcopenic obesity in patients with head and neck cancer is predictive of critical weight loss during radiotherapy.

The impact of computed tomography-defined sarcopenia on outcomes in head and neck cancer has been well described. Sarcopenic obesity (SO) (depleted muscle mass combined with obesity) may pose a more serious risk than either condition alone. We investigated SO and...
๐Ÿ—“๏ธ 2024-09-30
๐Ÿ“ฐ Publication: British Journal Of Nutrition
Read MoreSarcopenic obesity in patients with head and neck cancer is predictive of critical weight loss during radiotherapy.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!